https://www.epo.org/de/boards-of-appeal/decisions/t230868eu1
T 0868/23 (CAR T-cells/2SEVENTY BIO) vom 17.06.2025
2seventy bio17 06086823car
https://www.businesswire.com/news/home/20230912518500/en/2seventy-bio-Announces-Strategic-Restructuring-to-Prioritize-Growth-of-Abecma-Streamline-Pipeline-Advancement-and-Preserve-Financial-Runway
2seventy bio Announces Strategic Restructuring to Prioritize Growth of Abecma, Streamline Pipeline...
2seventy bio, Inc. (Nasdaq: TSVT), today announced a restructuring of its business operations and research and development model to significantly reduce cost...
2seventy bio
https://www.biospace.com/2seventy-bio-reports-first-quarter-2024-financial-results-and-recent-operational-progress
2seventy bio Reports First Quarter 2024 Financial Results and Recent Operational Progress - BioSpace
May 9, 2024 - 2seventy bio, Inc., reported financial results and recent highlights for the first quarter ended March 31, 2024.
2024 financial results
https://www.biospace.com/2seventy-bio-reports-fourth-quarter-and-full-year-2023-financial-results-and-recent-operational-progress
2seventy bio Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational...
Mar 6, 2024 - 2seventy bio, Inc., a leading immuno-oncology cell therapy company, reported financial results and recent highlights for the fourth quarter and full year ended...